Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 11/20 | 0.51 |
| ▸ | JAK3 | P52333 | 9/20 | 0.51 |
| ▸ | PTK2 | Q05397 | 9/20 | 0.51 |
| ▸ | AXL | P30530 | 1/20 | 0.43 |
| ▸ | NEK2 | P51955 | 1/20 | 0.43 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.42 |
| ▸ | INSR | P06213 | 1/20 | 0.42 |
| ▸ | IGF1R | P08069 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 2/20 | 0.40 |
| ▸ | AURKA | O14965 | 1/20 | 0.40 |
| ▸ | CDK4 | P11802 | 1/20 | 0.40 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.39 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 2/20 | 0.38 |
| ▸ | JAK1 | P23458 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19921078 | 0.90 | ALK (0.47) | JAK2JAK3PTK2AXLNEK2 | |
| SCHEMBL19921123 | 0.90 | EGFR (0.47) | JAK2JAK3PTK2ALKINSR | |
| SCHEMBL19921065 | 0.89 | PTK2 (0.40) | JAK2JAK3PTK2ALKINSR | |
| SCHEMBL19921187 | 0.87 | ALK (0.50) | JAK2JAK3PTK2AXLNEK2 | |
| SCHEMBL19921091 | 0.85 | PTK2 (0.52) | JAK2JAK3PTK2ALKBRD4 | |
| SCHEMBL20546889 | 0.85 | JAK2 (0.38) | JAK2JAK3PTK2ALK | |
| SCHEMBL20546956 | 0.83 | PTK2 (0.51) | JAK2PTK2ALKINSRIGF1R | |
| SCHEMBL19921176 | 0.82 | FLT3 (0.44) | PTK2ALKINSRIGF1RCDK4 | |
| SCHEMBL19921093 | 0.81 | TTK (0.50) | JAK2JAK3PTK2AXLNEK2 | |
| SCHEMBL19921204 | 0.81 | ALK (0.60) | JAK2JAK3PTK2AXLNEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3290420-B1 | PYRIMIDINE PYRROLE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION, AND USES THEREOF | UNIV XIAMEN (CN) | 2020-12-09 | — | — | EP | claimed |
| US-20180312508-A1 | PYRIMIDOPYRROLE COMPOUNDS, METHOD FOR PREPARING THE SAME, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME AND USES THEREOF | XIAMEN UNIVERSITY (CN) | 2018-11-01 | — | — | US | claimed |
| EP-3290420-A1 | PYRIMIDINE PYRROLE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION, AND USES THEREOF | Xiamen University (CN) | 2018-03-07 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180312508-A1 | PYRIMIDOPYRROLE COMPOUNDS, METHOD FOR PREPARING THE SAME, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME AND USES THEREOF | TPMT, DHPS, TYMP | JAK2 89/4885JAK3 112/4885PTK2 4325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.